2C-G-5

Last updated

2C-G-5
2C-G-5.svg
Clinical data
Other names3,4-Norbornyl-2,5-DMPEA; 3,4-Norbornyl-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-3,4-norbornylphenethylamine; 3,6-Dimethoxy-4-(2-aminoethyl)benzonorbornane
Routes of
administration 		Oral [1]
Drug class Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Onset of action 1–2 hours [1]
Duration of action 32–48 hours [1]
Identifiers
  • 2-(3,6-dimethoxy-4-tricyclo[6.2.1.02,7]undeca-2,4,6-trienyl)ethanamine
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C15H21NO2
Molar mass 247.338 g·mol−1
3D model (JSmol)
  • COC1=C2C3CCC(C3)C2=C(C(=C1)CCN)OC
  • InChI=1S/C15H21NO2/c1-17-12-8-11(5-6-16)15(18-2)14-10-4-3-9(7-10)13(12)14/h8-10H,3-7,16H2,1-2H3
  • Key:ASPWVWSIJQTXDB-UHFFFAOYSA-N

2C-G-5, also known as 3,4-norbornyl-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and 2C families. [1] [2] [3] [4] It is one of several homologues of 2C-G (3,4-dimethyl-2,5-dimethoxyphenethylamine). [1] [2] [3] [4]

Contents

The drug has a dose of 10 to 16 mg orally, an onset of 1 to 2 hours, a peak of 2.5 to 3 hours, and a duration of 32 to 48 hours. [1] [2] [3] It produces psychedelic effects including visuals, clear and cosmic thinking, and 2C-B-like enhanced eroticism, among others. [1] 2C-G-5 is among the most potent of the 2C psychedelics. [1] [2] [3] However, its duration is described as too long, interfering with sleep and resulting in subsequent-day consequences like tiredness and sleepiness. [1]

The chemical synthesis of 2C-G-5 has been described. [1]

2C-G-5 was first described in the literature by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). [1] [2] [3] [4]

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 11 Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628. "2C-G-5".
  2. 1 2 3 4 5 Jacob P, Shulgin AT (1994). "Structure-activity relationships of the classic hallucinogens and their analogs" (PDF). NIDA Research Monograph. 146: 74–91. PMID   8742795. Archived from the original (PDF) on August 5, 2023.
  3. 1 2 3 4 5 Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN   978-0-12-433951-4 . Retrieved 1 February 2025.
  4. 1 2 3 Shulgin A, Manning T, Daley P (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds . Vol. 1. Berkeley: Transform Press. ISBN   978-0-9630096-3-0.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.